Aburustum NR, Gemignani ML, Moore K, Sonoda Y, Venkatraman E, Brown C, Poynor E, Chi DS, Barakat RR. Total laparoscopic radical hysterectomy with pelvic lymphadenectomy using the argon-beam coagulator - pilot data and comparison to laporotomy. Gynecol Onc 2003;91:402-409.
Aburustum NR, Sonoda Y, Chi DS, Teoman H, Dizon DS, Venkatraman E, Barakat RR. The effects of CO2 pneumoperitoneum on the survival of women with persistent metastatic ovarian cancer. Gynecol Onc 2003;90:431-434.
Alaminos M, Mora J, Cheung NKV, Smith A, Qin J, Chen LS, Gerald WL. Genome wide analysis of gene-expression associated with mycn in human neuroblastoma. Cancer Res 2003;63:4338-4546.
Alektiar KM, Venkatraman E, Aburustum, Barakat RR. Is endometrial carcinoma intrinsically more aggressive in elderly patients. Cancer 2003;98:2368-2377.
Aleman M, Karakiewicz PI, Kupelian P, Kattan MW, Graefen M, Cagiannos I, Eastham J, Scardino PT, Huland H, Klein EA. Age and PSA predict the likelihood of organ-confined disease in men presenting with PSA < 10 Ng/Ml: implications for screening. Urology 2003; 62(1):70-4.
Antonescu CR., Sommer G, Sarran L, Tschernyavsky SJ, Riedel E, Woodruff JM, Robson M. Maki R, Brennan MF, Ladanyi M, DeMatteo RP, Besmer P: Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clinical Cancer Research 2003; 9:3329-3337.
Aung L, Gorlick R, Healey JH, Shi W, Thaler HT, Shorter NA, Huvos AG, Meyers PA. Metachronous skeletal osteosarcoma in patients treated with adjuvant and neoadjuvant chemotherapy for nonmetastatic osteosarcoma. J Cl Oncol 2003;21:342-348.
Azzoli CG, Miller VA, Ng KK, Krug LM, Spriggs DR, Tong WP, Riedel E, Kris MG: A phase I trial of perillyl alcohol in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology 2003. 51:493-498
Bach AM, Hann LE, Shi W, Giess CS, Yoo HH, Sheinfeld J, Thaler HT. Is there an increased incidence of contralateral testicular cancer in patients with intratesticular microlithiasis? Amer J Roentgenol 2003;180:497-500.
Bach PB, Kattan MW, Thornquist MD, Kris MG, Tate RC, Barnett MJ, Hsieh LJ, Begg CB. Variations in lung cancer risk among smokers. J Natl Cancer Inst 2003; 95: 470-78.
Bach PB, Kelley MJ, Tate RC, McCrory DC. Screening for lung cancer: a review of the current literature. Chest 2003; 123:72S-82S.
Bach PB, Niewoehner DE, Black WC. Screening for lung cancer: the guidelines. Chest 2003; 123: 83S-88S.
Bach PB. "Unequal Treatment: Confronting racial and ethnic disparities in healthcare [book review]." The New England Journal of Medicine 2003; 349: 1296-7.
Bandera EV, Kushi LH, Olson SH, Chen WY, Muti P. Alcohol consumption and endometrial cancer: some unresolved issues. Nutrition & Cancer 2003;45:24-9.
Bastian BC, Olshen AB, Kashani-Sabet M, LeBoit PE, Pinkel D. Classifying melanocytic tumors based on DNA copy number changes. American Journal of Pathology 2003;1765-1770.
Beck SDW, Patel MI, Snyder ME, Kattan MW, Motzer RJ, Reuter VE, Russo P. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol 2003; 11(1):71-77.
Begg CB, Scardino PT. Taking stock of volume-outcome studies (Editorial). Journal of Clinical Oncology 2003;21:393-394.
Begg CB. Response to Correspondence. On the use of familial aggregation in population-based case probands for calculating penetrance (Letter). Journal of the National Cancer Institute 2003;95:77-78.
Bennett CL, Somerfield MR, Pfister DG, Tomori C, Yakren S, Bach PB. Perspectives on the value of American Society of Clinical Oncology clinical guidelines as reported by oncologists and health maintenance organizations. J Clin Oncol 2003; 21: 937-41.
Berriz GF, King OD, Bryand B, Sander C, Roth FP. Characterizing gene sets with FuncAssociate. Bioinformatics 2003;19:2502-2504.
Berwick M. Soft Tissue Sarcoma. IN Schottenfeld D, Fraumeni J, Cancer Epidemiology and Prevention, Third Edition. 2003.
Bianco FJ Jr, Kattan MW, Scardino PT, Powell IJ, Pontes JE, Wood DP Jr, Moul JW. Radical prostatectomy nomograms in black American men: accuracy and applicability. J Urol 2003;170(1):73-77.
Bondoc AY, Bach PB, Sklarin NT, Vander Els NJ. Arterial desaturation syndrome following pleurodesis with talc slurry: incidence, clinical features, and outcome. Cancer Invest. 2003; 21:848-54.
Brogi E, Robson M, Panageas KS, Casadio C, Marie-Ljung B, Montgomery L. Ductal lavage in patients undergoing mastectomy for mammary carcinoma: a correlative study. Cancer 2003;98:2170-2176.
Burke JM, Caron PC, Papadopoulos EB, Divgi CR, Sgouros G, Panageas KS, Finn RD, Larson SM, O'Reilly RJ, Scheinberg DA, Jurcic JG. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias. Bone Marrow Transplant 2003;32:549-556.
Cagiannos I, Karakiewicz P, Eastham JA, Ohori M, Rabbani F, Gerigk C, Reuter V, Graefen M, Hammerer PG, Erbersdobler A, Huland H, Kupelian P, Klein E, Quinn DI, Henshall SM, Grygiel JJ, Sutherland RL, Stricker PD, Morash CG, Scardino PT and Kattan MW. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol 2003; 170: 1798-1803.
Cagiannos I, Karakiewicz P, Graefen M, Eastham JA, Ohori M, Rabbani F, Reuter V, Wheeler T, Kupelian P, Klein E, Huland H, Hammerer P, Erbersdobler A, Schroeder F, Wildhagen M, Quinn DI, Henashall SM, Grygiel JJ, Sutherland Rl, Stricker PD, Morash CG, Scardino PT, Kattan MW. Is year of radical prostatectomy a predictor of outcome in prostate cancer? J Urol 2004; 171:692-696.
Carroll PR, Benaron DA, Blackledge G, Coakley FV, D'Amico AV, Higano CS, Iversen P, Kattan MW, Nanus DM, Nelson JB, Oh W, Roach III M, Sellers WR, Smith MR, McMann MC, Kantoff PW. Third International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection, and Treatment. J Urol 2003; 170: S3-S5.
Cassileth BR, Vickers AJ, Magill LA. Music therapy for mood disturbance during hospitalization for autologous stem cell transplantation: a randomized controlled trial. Cancer 2003;98:2723-2729.
Cassileth BR, Vickers AJ. Questionable cancer therapies. In: Cancer Medicine Ed by JF Holland, E Frei, R Bast, D Kufe, R Pollock, R Weichselbaum. Hamilton, Canada: BC Decker Inc (2002 edition in press).
Cassileth BR, Vickers AJ. Localized Prostate Cancer: Complementary and alternative therapies. Urologic Clinics of North America 2003;30:369-76
Chen, S. X. and Qin, J. Empirical likelihood based confidence intervals for data with possible zero observations. Statistics and Probability Letters 2003;65;29-37.
Cho D, Di Blasio C, Rhee AC, and Kattan MW. Prognostic factors for survival in patients with hormone-refractory prostate cancer (HRPC) after initial androgen deprivation therapy (ADT). Urol Oncol: Seminars and Original Investigations 2003 Jul-Aug;21(4):282-91.
D'Angelica M, Fong Y, Weber S, Gonen M, DeMatteo R, Conlon K, Blumgart LH, Jarnagin W. Prospective evaluation of staging laparoscopy in 401 patients with potentially resectable 1-degrees and 2-degrees hepatobiliary malignancies. Ann Surg Oncol 2003;10:183-189.
DeCandia P, Solit DB, Giri D, Brogi E, Siegel PM, Olshen AB, Muller WJ, Rosen N, Benezra R. Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/neu-dependent breast tumors. Proc Natl Acad Sci.2003;12337-12342.
Di Blasio CJ, Rhee AC, Cho D, Scardino PT and Kattan MW. Predicting Clinical Endpoints: Treatment Nomograms in Prostate Cancer. Seminars in Oncology 2003:231-252.
Dizon DS, Dupont J, Anderson S, Sabbatini P, Hummer A, Aghajanian C, Spriggs D. Treatment of recurrent ovarian cancer; a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experience. Gynecology Oncology 2003;91:584-590.
Donat SM, Bayuga S, Herr HW, Berwick M. Fluid intake the risk of tumor recurrence in patients with superficial bladder cancer. J Urology 2003 170 (5):1777-80.
Drucker B, Bacik J, Ginsberg M, Marion S, Russo P, Mazumdar M, Motzer R. Phase II trial of ZD1839 (IRESSA(TM)) in patients with advanced renal-cell carcinoma. Inv New Dr 2003;21:341-345.
Drucker B, Mazumdar M, Motzer RJ. Prognostic factors for metastatic kidney cancer. Cancer Treatment and Research, Kluwer Academic Publishers, Norwell, MA. 2003;pp 239-154.
Duffield-Lillico AJ, Dalkin BL, Reid ME, Turnbull BW, Slate EH, Jacobs ET, Marshall JR, Clark LC. Selenium supplementation, baseline plasma selenium status, and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int 2003;91:608-612.
Duffield-Lillico AJ, Slate EH, Reid ME, Turnbull BW, Wilkins PA, Combs GF Jr, Park HK, Gross EG, Graham GF, Stratton MS, Marshall JR, Clark LC. Selenium supplementation and the secondary prevention of non-melanoma skin cancer in a randomized trial. J Natl Cancer Inst 2003;95:1477-1481.
Dyke JP, Panicek DM, Healey JH, Meyers PA, Huvos AG, Schwartz LH, Thaler HT, Tofts PS, Gorlick R, Koutcher JA, Ballon D. Necrotic fraction estimation of osteogenic and Ewing's sarcomas undergoing induction chemotherapy using dynamic enhanced MR imaging. Radiology 2003; 228:271-278.
Eastham JA, Kattan MW, Riedel E, Begg C, Wheeler T, Gerigk C, Gonen M, Reuter V, Scardino PT. Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. J Urol 2003; 170:2292-2295.
Eastham JA, Riedel E, Latkany L, Fleisher M, Schatzkin A, Lanza E, Shike M. Dietary manipulation, ethnicity, and serum PSA levels. Urology 2003. 62(4):677-682.
Eastham JA, Riedel E, Scardino PT, Shike M, Fleisher M, Schatzkin A, Lanza E, Latkany L, Begg CB. Variation of serum prostate specific antigen levels: an evaluation of year-to-year fluctuations in a well defined cohort of men. JAMA 2003;289:2695-2700.
Eastham JA, Scardino PT, Begg CB. Reliability and validity of prostate-specific antigen - reply (Letter). Journal of the American Medical Association 2003;290:1705-1706.
Eitan R, Gemignani ML, Venkatraman ES, Barakat KK, Aburustum NR. Breast cancer metastatic to abdomen and pelvis. Role of surgical resection. Gynecol Onc 2003;90:397-401.
Engel LS, Chow WH, Vaughan TL, Gammon MD, Risch HA, Stanford JL, Schoenberg JB, Mayne ST, Dubrow R, Rotterdam H, West AB, Blaser M, Blot WJ, Gail MH, Fraumeni JF. Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst 2003;95:1404-1413.
Enright AJ, John B, Gaul U, Tuschl T, Sander C, Marks DS. MicroRNA targets in drosophila. Genome Biology 2003;5:R1.
Fearn PA, Regan K, Sculli F, Katz J, Kattan MW. A chronological database as backbone for clinical practice and research data management. Proceedings of the Sixteenth Annual IEEE Symposium on Computer-Based Medical Systems, New York, NY, 2003; 9-15.
Flores RM, Akhurst T, Gonen M, Larson SM, Rusch VW. Positron-emission-tomography efines metastatic-disease but not locoregional disease in patients with malignant pleural mesothelioma. Journal of Thoracic Surgery 2003;126:11-16.
Gemignani ML, Schlaerth AC, Bogomolniy F, Barakat RR, Lin O, Soslow R, Venkatraman E, Boyd J. Rose of KRAS and BRAF gene-mutations in mucinous ovarian carcinoma. Gynecol Onc 2003;90:378-381.
Gonen M, Banerjee D, Bertino J, Kemeny N. Can colorectal cancer patients with thymidylate synthase overexpressing liver metastases have an overall survival advantage with hepatic arterial infusion alone - reply (Letter). J Clin Oncol 2003;21:3544-3545.
Gonen M, Hummer A, Zervoudakis A, Sullivan D, Fong Y, Banerjee D, Klimstra D, Cordon-Cardo C, Bertino J, Kemeny N. Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer. J Clin Oncol 2003;21:406-412.
Gonen M, Westfall PH, Johnson WO. Bayesian multiple testing for two-sample multivariate endpoints. Biometrics 2003;59:76-82.
Gonen M. Planning for subgroup analysis: a case study of treatment-marker interaction in metastatic colorectal cancer. Controlled Clinical Trials 2003;24:355-363.
Gonzales GR, Tuttle SL, Thaler HT, Manfredi PL. Central pain in cancer patients. J Pain 2003;4:351-354
Graefen M, Augustin H, Karakiewicz PI, Hammerer PG, Haese A, Palisaar J, Fernandez S, Noldus J, Erbersdobler A, Cagiannos I, Scardino PT, Kattan MW, and Huland H. Can nomograms derived in the U.S. applied to German patients? A study about the validation of preoperative nomograms predicting the risk of recurrence after radical prostatectomy (in German). Urologe A 2003;42(5):685-92.
Graefen M, Ohori M, Karakiewicz PI, Cagiannos I, Hammerer PG, Haese A, Erbersdobler A, Henke RP, Huland H, Wheeler TM, Slawin K, Scardino PT, Kattan MW. Assessment of the enhancement in predictive accuracy provided by systematic biopsy in predicting outcome for clinically localized prostate cancer. J Urol 2004; 171:200-203.
Groeger JS, Bach PB. Consider saying yes [editorial]. Crit Care Med 2003; 31: 320-1.
Gruber SB, Ellis NA, Scott KK, Almog R, Kolachana P, Bonner JD, Kirchoff T, Tomsho LP, Nafa K, Pierce H, Low M, Satagopan J, Rennert H, Huang H, Greenson JK, Groden J, Rapaport B, Shia J, Johnson S, Gregersen PK, Harris CC, Boyd J, Rennert G, Offit K. BLM Heterozygosity and the risk of colorectal cancer. Science 2002;297:2013.
Gyorki DE, Busam K, Panageas K, Brady MS, Coit DG. Sentinel lymph node biopsy for patients with cutaneous desmoplastic melanoma. Annals of Surgical Oncology 2003;10:403-407.
Haese A, Graefen M, Becker C, Noldus J, Katz J, Cagiannos I, Kattan MW, Scardino PT, Huland E, Huland H, Lilja H. The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer. Prostate. 2003; 15:54(3):181-6.
Halabi S, Small EJ, Kantoff PW, Kattan MW, Dawson NA, Levine EG, Blumenstein BA, Vogelzang NJ. Prognostic model for predicting survival in men with hormone refractory metastatic prostate cancer. J Clin Oncol 2003; 21(7):1232-1237.
Hamlin PA, Zelenetz AD, Kewalramani T, Qin J, Satagopan JM, Verbel D, Noy A, Portlock CS, Straus DJ, Yahalom J, Nimer SD, Moskowitz CH. Age-adjusted international prognostic index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2003;102:1989-1996.
Hann LE, Kim CM, Gonen M, Barakat R, Choi PH, Bach AM. Sonohysterography compared with endometrial biopsy for evaluation of the endometrium in tamoxifen-treated women. Journal of Ultrasound in Medicine 2003, 22: 1173-1179.
Hedvat CV, Comenzo RL, Teruya-Feldstein J, Olshen AB, Ely SA, Osman K, Zhang YN, Kalakonda N, Nimer SD. Insights into extramedullary tumor-cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma. Br J Haem 2003;122:728-744.
Heffner LJ, Elkin E, Fretts RC. Impact of labor induction, gestational age, and maternal age on cesarean delivery rates. Obstetrics and Gynecology, 2003;102:287-293.
Holzbeierlein J, Lal P, La Tulippe E, Smith A, Satagopan J, Zhang L, Ryan C, Smith S, Scher H, Scardino P, Reuter V, Gerald WL. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. American Journal of Pathology 2003;164:217-227.
Hu JC, Elkin EP, Pasta DJ, Lubeck DP, Kattan MW, Carroll PR, Litwin MS. Predicting quality of life after radical prostatectomy: results from CaPSURE. J Urol 2004; 171(2):703-708.
Huynh PM, Glusac EJ, Alvarez-Franco M, Berwick M, Bolognia J. Numerous small darkly pigmented melanocytic nevi: The cheetah phenotype. Journal of the American Academy of Dermatology. 2003; 48(5):707-12..
Hwu WJ, Krown SE, Menell JH, Panageas KS, Merrell J, Lamb LA, Williams LJ, Quinn CJ, Foster T, Chapman PB. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol 2003;21:3351-3356.
Iliopoulos I, Tsoka S, Andrade MA, Enright AJ, Carroll M, Poullet P, Promponas V, Liakopoulos T, Palaios G, Pasquier C, Hamodrakas S, Tamames J, Yagnik AT, Tramontano A, Devos D, Blaschke C, Valencia A, Brett D, Martin D, Leroy C, Rigoutsos I, Sander C, Ouzounis CA. Evaluation of annotation strategies using an entire genome sequence. Bioinformatics 2003;19:717-726.
Ilson DH, Bains M, Kelsen DP, O'Reilly E, Karpeh M, Coit D, Rusch V, Gonen M, Wilson K, Minsky BD. Phase I trial of escalating dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer. J Clin Oncol 2003;21:2926-2932.
Karakiewicz PI, Kattan MW, Tanguay S, Elhilali MM, Bazinet M, Scardino PT and Aprikian AG. Cross cultural validation of the UCLA Prostate Cancer Index. Urology 2003;61(2):302-7.
Kattan MW, Eastham JA, Wheeler TM, Maru N, Scardino PT, Erbersdobler A, Graefen M, Huland H, Koh H, Shariat SF, Slawin KM, Ohori M. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 2003; 170: 1792-1797.
Kattan MW, Eastham JA. Algorithms for PSA recurrence after treatment of localized prostate cancer. Clinical Prostate Cancer 2003;1:221-226.
Kattan MW, Heller G, Brennan MF. A competing-risks nomogram for sarcoma-specific death following local recurrence. Stat Med 2003; 22: 3515-3525.
Kattan MW, Karpeh MS, Mazumdar M, Brennan MF. Postoperative nomogram for disease specific survival after an RO resection for gastric carcinoma. J Clin Oncol 2003;21:3647-3650.
Kattan MW, Shariat SF, Andrews B, Zhu K, Canto E, Matsumoto K, Scardino PT, Ohori M, Wheeler TM, Slawin KM. The addition of interleukin-6 soluble receptor and transforming growth factor B1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol 2003; 21(19): 3573-3579.
Kattan MW, Zelefsky MJ, Kupelian PA, Cho D, Scardino PT, Fuks Z, Leibel SA. A pretreatment nomogram that predicts 5 year probability of metastasis following 3-D conformal radiation therapy for localized prostate cancer. J Clin Oncol 2003; 21(24):4568-4571.
Kattan, MW. Comparing treatment outcomes using utility assessment for health-related quality of life. Oncology 2003; 17(12): 1687-1693.
Kattan, MW. Comparison of Cox regression with other methods for determining prediction models and nomograms. J Urol 2003; 170: S6-S10.
Kattan MW. Nomograms are superior to staging and risk grouping systems for identifying high-risk patients: preoperative application in prostate cancer. Curr Opin Urol 2003;13:111-116.
Kattan MW. Judging new markers by their ability to improve predictive accuracy. J. Natl Cancer Inst. 2003;95:634-635.
Kattan MW. Better predictions for patients. Family Urology 2003;8:11-15.
Katz MS, Zelefsky MJ, Venkatraman ES, Fuks Z, Hummer A, Leibel S. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. Journal of Clinical Oncology 2003; 21:483-489.
Kemeny N, Jarnagin W, Gonen M, Stockman J, Blumgart L, Sperber D, Hummer A, Fong Y. Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer. J Cl Oncol 2003;21:3303-3309.
Kewalramani T, Nimer SD, Zelenetz AD, Malhotra S, Qin J, Yahalom J, Moskowitz CH. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory hodgkins disease or aggressive non hodgkins lymphoma. Bone Mar Tr 2003;32:673-679.
Kim YM, Bujold E, Chaiworapongsa T, Gomez R, Yoon BH, Thaler HT, Rotmensch S, Romero R. Failure of psysiological transformation of the spiral arteries in patients with preterm labor and intact membranes. Am J Obstet Gynecol 2003;189:1063-1069.
Koehne G, Doubrovin M, Doubrovin E, Zanzonico P, Gallardo HF, Ivanova A, Balatoni J, Teruya-Feldstein J, Heller G, May C, V Ponomarev, Ruan S, Finn R, Blasberg RG, Bornmann W, Riviere I, Sadelain M, O'Reilly RJ, Larson SM, Tjuvajev JG. Serial in-vivo imaging of the targeted migration of human HSV-TK transduced antigen specific lymphocytes. Nature Biotechnology 2003; 21:405-413.
Koh H, Kattan MW, Scardino PT, Suyama K, Maru N, Slawin K, Wheeler TM, Ohori M. A nomogram to predict seminal vesicle invasion by the extent and location of cancer in systematic biopsy results. J Urol 2003; 170(4): 1203-1208.
Kolb EA, Kushner BH, Gorlick R, Laverdiere C, Healey JH, LaQuaglia MP, Huvos AG, Qin J, Vu HT, Wexler L. Long-term event free survival after intensive chemotherapy for Ewings family of tumors in children and young adults. J Cl Oncol 2003;21:3423-3430.
Kooby DA, Stockman J, Ben-Porat L, Gonen M, Jarnagin WR, Dematteo RP, Tuorto S, Wuest D, Blumgart LH, Fong Y. Influence of transfusions on perioperative and long-term outcome in patients following hepatic resection for colorectal metastases. Annals of Surgery 2003;237:860-70.
Kornick C, Kilborn M, Santiago-Palma J, Schulman G, Thaler H, Keefe D, Katchman A, Pezzullo J, Ebert S, Woosley R, Payne R, Manfredi P. QTc interval prolongation with intravenous methadone. Pain 2003;105:499-506.
Krug LM, Azzoli CG, Kris MG, Miller VA, Khokhar NZ, Tong W, Ginsberg MS, Venkatraman E, Tyson L, Pizzo B, Baez V, Ng KK, Sirotnak FM. 10 propargyl-10 deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer. Clin Cancer Res 2003;9:2072-2078.
Kutler DI, Auerbach AD, Satagopan J, Giampietro PF, Batish SD, Huvos AG, Goberdhan A, Shah JP, Singh B. High incidence of head and neck squamous cell carcinoma in patients with Fanconi Anemia. Archives of Otolaryngology Head and Neck Surgery 2003; 129: 106-112.
Kutler DI, Singh B, Satagopan J, Batish SD, Berwick M, Giampietro PF, Hanenberg H, Auerbach AD. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood 2003; 101: 1249-1256.
Kutler DI, Singh B, Satagopan JM, Berwick M, Giampietro PF, Auerbach AF (2002): A 20 year perspective of the International Fanconi Anemia Registry (IFAR). Blood 2003;101:1249-1256.
Kutler DI, Wreesmann VB, Goberdhan A, Ben-Porat L, Satagopan J, Ngai I, Huvos AG, Giampietro P, Levran O, Pujara K, Diotti R, Carlson D, Huryn LA, Auerbach AD, Singh B. Human papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi anemia patients. J NCI 2003;95:1718-1721.
Lee CT, Genega EM, Hutchinson B, Fearn PA, Kattan MW, Russo P, Reuter VE. Conventional (clear cell) renal carcinoma metastases have greater bcl-2 expression than high-risk primary tumors. Urol Oncol 2003; 21(3):179-84.
Leitao MM Jr, Hummer A, Dizon DS, Aghajanian C, Hensley M, Sabbatini P, Venkatraman E, Springgs DR. Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy. Gynecol Oncol 2003;91:123-129.
Littenberg B, Partilo S, Licata A, Kattan MW. Paper Standard Gamble: The reliability of a paper questionnaire to assess utility. Medical Decision Making 2003; 23(6): 480-488.
Lopez-Corona E, Ohori M, Scardino PT, Reuter VE, Gonen M, Kattan MW, Catalona WJ. A nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session. Journal of Urology, 2003, 170:1184-1188.
Lucito R, Healy J, Alexander J, Reiner A, Esposito D, Chi M, Rodgers L, Brady A, Sebat J, Troge J, West JA, Rostan S, Nguyen KC, Powers S, Ye KQ, Olshen A, Venkatraman E, Norton L, Wigler M. Representational oligonucleotide microarray analysis: a high-resolution method to detect genome copy number variation. Genome Res 2003;13:2291-2305.
Maj JG, Paris F, Haimovitz-Friedman A, Venkatraman E, Kolesnick R, Fuks Z. Microvascular function regulates intestinal crypt response to radiation. Cancer Res 2003;63:4338-4341.
Mazumdar M and Liu A. Group sequential design for comparative diagnostic accuracy studies, Stat in Medicine 2003;22:727-739.
Mazumdar M, Bacik J, Tickoo SK, Bobrzynski D, Donadio A, Bajorin DF, Motzer RJ, Reuter VE, Bosl GJ. Cluster analysis of p53 and ki67 expression, apoptosis, alpha-fetoprotein and human chorionic gonadotrophin discovers a good prognostic subgroup within embryonal carcinoma germ cell tumor, J Clin Oncol 2003; 21:2679-2688.
Mazumdar M, Smith A, Bacik J. Methods for categorizing a prognostic variable in a multivariable setting. Stat in Medicine 2003;22:559-571.
Meyerhart JA, Catalano PJ, Schrag D, Ayanian JZ, Haller DG, Mayer RJ, MacDonald JS, Benson AB, Fuchs CS. Association of hospital procedure volume and outcomes in patients with colon cancer at high risk for recurrence. Ann Int Med 2003;139:649-657.
Moore HG, Akhurst T, Larson SM, Minsky BD, Mazumdar M, Guillem JG. A case-controlled study of 18-fluorodeoxyglucose positron emission tomography in the detection of pelvic recurrence in previously irradiated rectal cancer patients. J Am Coll Surg 2003;197: 22-28
Moore HG, Riedel E, Minsky BD, Saltz L, Paty P, Wong D, Cohen AM, Guillem JG: Adequacy of 1-cm distal margin after restorative rectal cancer resection with sharp mesorectal excision and preoperative combined-modality therapy. Annals of Surgical Oncology 2003;10:80-85.
Mora J, Filippa DA, Qin J, Wollner N. Lymphoblastic lymphoma of childhood and the LSA(2)-L-2 protocol - the 30 year experience at Memorial Sloan-Kettering Cancer Center. Cancer 2003;98:1283-1291.
Muscat JE, Chen SQ, Richie JP Jr, Altorki NK, Citron M, Olson S, Neugut AI, Stellman SD. Risk of lung carcinoma among users of nonsteroidal antiinflammatory drugs. Cancer 2003;97:1732-6.
Nathanson DR, Espat NJ, Nash GM, D'Alessio M, Thaler TH, Minsky BD, Enker W, Wong D, Guillem J, Cohen A, Paty PB. Evaluation of preoperative and postoperative radiotherapy on long-term functional results of straight coloanal anastomosis. Dis Colon Rectum 2003; 46:888-894.
Negin B, Riedel E, Oliveria SA, Berwick M, Coit DG, Brady MS. Symptoms and signs of primary melanoma: important indicators of Breslow depth. Cancer 2003; 98(2):344-8.
Offit K, Pierce H, Kirchoff T, Kolachana P, Rapaport B, Gregersen P, Johnson S, Yossepowitch O, Huang H, Satagopan J, Robson M, Scheuer L, Nafa K, Ellis N. Frequency of CHEK2*1100delC in New York breast cancer cases and controls. BMC Medical Genetics 2003. 4:1.
Ohori M, Kattan MW, Utsunomiya T, Suyama K, Scardino PT, and Wheeler TM. Do impalpable (T1c) prostate cancers visible on ultrasound differ from those not visible? J Urol 2003;169(3):964-8.
Oliveria SA, Sachs D, Belasco KT, Halpern AC. Adoption of new technologies for early detection of melanoma in dermatologic practice. J Am Acad Dermatol. 2003;49:955-9.
Panageas KS, Begg MD, Grbic JT, Lamster IB. Analysis of multiple 2x2 tables with site-specific periodontal data. Journal of Dental Research 2003;82:514-517.
Panageas KS, Schrag D, Riedel E, Bach PB, Begg CB. The effect of clustering on the association of procedure volume and surgical outcomes. Annals of Internal Medicine, 2003;139:658-65.
Pandit-Taskar N, Gonen M, Kurg L, Larson SM. Prognostic value of 18FDG-PET imaging in small cell lung cancer. European Journal of Nuclear Medicine & Molecular Imaging 2003;30:78-84.
Patel MI, Simmons R, Kattan MW, Motzer R, Reuter V, and Russo P. Long term follow up of bilateral sporadic renal tumors. Urology 2003;610(5):921-925.
Phelan DL, Oliveria SA, Christos PJ, Dusza SW, Halpern AC. Skin self-examination in patients at high risk for melanoma: a pilot study Oncol Nurs Forum. 2003;30:1029-36.
Pothuri B, Ramondetta L, Martino M, Alektiar K, Eifel PJ, Deavers MT, Venkatraman E, Soslow RA, Barakata RR. Development of endometrial cancer after radiation treatment for cervical carcinoma. Obstet Gyn 2003;101:941-945.
Pothuri B, Vaidya A, Aghajanian C, Venkatraman E, Barakat RR, Chi DS. Palliative surgery for bowel obstruction in recurrent ovarian-cancer - an updated version. Gynecol Onc 2003;89:306-313.
Potters L, Kattan MW, Fearn P. A chronological database to support outcomes research in prostate cancer. Int J Radiat Oncol Biol Phys 2003; 56(5):1252-1258.
Potters L, Purrazzella R, Brustein S, Fearn P, Huang D, Leibel SA, Kattan MW. The prognostic significance of Gleason grade in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2003; 1:56(3):749-54.
Prabhu VC, Bilsky MH, Jambekhar K, Panageas KS, Boland PJ, Lis E, Heier L, Nelson PK. Current results of preoperative embolization for metastatic spinal neoplasms, Journal of Neurosurgery 2003;98:156-164.
Qin J and Fokianos K. Discussion of the paper "A theory of statistical models for Monte Carlo integration" by A. Kong, P. McCullagh, X-L, Meng, D. Nicolae, Z. Tan. J. R. Statist. Soc. B 2003;65:611.
Qin J, Berwick M, Ashbolt R, Dwyer T. Quantifying the change of melanoma incidence by Breslow thickness. Biometrics 2003;58:665-670.
Qin J. and Zhang B. Using logistic regression procedures for estimating receiver operating characteristic curves. Biometrika 2003;90:585-596.
Ratzinger G, Reagan JL, Heller G, Busam KJ, Young JW. Differential CD52 expression by distinct myeloid dendritic cell subsets - implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft host interactions in transplantation. Blood 2003; 101:1422-1429.
Resnick MI, Gospodarowicz M, Gibod LB, Bono A, Brawer M, Elhilai M, Kattan MW, Lilja H, Murai M, O'Sullivan B, Turkes A, and Wein A: Markers and Prognostic Factors. In: Denis L, Bartsch G, Khoury S, Murai M, and Partin A (eds). Prostate Cancer. Health Publications: Paris; 2003. 49-89.
Risberg T, Vickers AJ, Bremnes RM, Wist EA, Kaasa S, Cassileth BR. Does alternative medicine use predict survival in cancer? European Journal of Cancer 2003;39: 372-377
Ross PL, Littenberg B, Fearn P, Scardino PT, Karakiewicz PI, Kattan MW. Paper standard gamble: a paper-based measure of standard gamble utility for current health. Int J Technol Assess Health Care 2003;19(1):135-147.
Sandberg DI, Bilsky MH, Kushner BH, Souweidane MM, Kramer K, Laquaglia MP, Panageas KS, Cheung NK. Treatment of spinal involvement in neuroblastoma patients. Pediatric Neurosurg 2003; 39:291-8.
Satagopan JM, Elston RC. Optimal two-stage genotyping in population-based association studies. Genetic Epidemiology 2003;25:149-157.
Satagopan JM, Panageas KS. A statistical perspective on gene expression data analysis. Statistics in Medicine 2003;22:481-499.
Satagopan JM, Smith AD. Statistical methods in genomics research. HeartDrug 2003;3:48-60.
Saunders CL, Begg CB. Kin-cohort evaluation of relative risks of genetic variants. Genetic Epidemiology 2003;24:220-229.
Schrag D, Hsieh LJ, Rabbani F, Bach PB, Herr H, Begg CB. Adherence to surveillance among patients with superficial bladder cancer. J Natl Cancer Inst 2003; 95; 588-97.
Schrag D, Panageas KS, Riedel E, Hsieh L, Bach PB, Guillem JG, Begg CB. Surgeon volume compared to hospital volume as a predictor of outcome following primary colon cancer resection. J of Surg Onc 2003; 83: 68-79.
Schwartz LH, Mazumdar M, Brown W, Smith A, Panicek DM. Variability in response assessment in solid tumors - effect of number of lesions chosen for measurement. Clin Canc R 2003;9:4318-4323.
Schwartz LH, Mazumdar M, Wang L, Smith A, Marion S, Panicek DM, Motzer RJ. Response assessment classification in patients with advanced renal-cell carcinoma treated on clinical trials - effect of measurement criteria and other parameters. Cancer 2003;98:1611-1619.
Sgouros G, Squeri S, Ballangrud AM, Kolbert K, Teitcher JB, Panageas KS, Finn RD, Divgi CR, Larson SM, Zelenetz AD. Correlation of tumor radiation absorbed dose with response is easier to find in previously untreated patients - Reply (Letter). J Nucl Med 2003;44:1543.
Sgouros G, Squeri S, Ballangrud AM, Kolbert KS, Teitcher JB, Panageas KS, Finn RD, Divgi CR, Larson SM, Zelenetz AD. Patient-specific, 3-D dosimetry in non-hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response. Journal of Nuclear Medicine 2003;44:260-268.
Shariat SF, Kattan MW, Erdamar S, Nguyen C, Scardino PT, Spencer DM, Wheeler TM, Slawin KM. Detection of clinically significant, occult prostate cancer metastases in lymph nodes using a splice variant-specific RT-PCR assay for human glandular kallikrein. J Clin Oncol 2003; 21(7):1223-1231.
Shariat SF, Roudier MP, Wilcox GE, Kattan MW, Scardino PT, Vessella RL, Erdamar S, Nguyen C, Wheeler TM, Slawin KM: Comparison of immunohistochemistry with RT-PCR for the detection of micrometastatic prostate cancer in lymph nodes. Cancer Res. 2003 Aug 1;63(15):4662-70.
Shariat, S, Kattan MW, Song W, Bernard D, Gottenger E, Wheeler TM, Slawin KM. (2003). Early postoperative peripheral blood reverse transcription PCR assay for prostate-specific antigen is associated with prostate cancer progression in patients undergoing radical prostatectomy. Cancer Res 2003; 63: 5874-5878.
Shia J, Ellis NA, Paty PB, Nash GM, Qin J, Offit K, Zhang XM, Markowitz AJ, Nafa K, Guillem JG. Value of histopathology in predicting microsatellite instability in hereditary nonpolyposis colorectal cancer and sporadic colorectal cancer. American Journal of Surgical Pathology 2003;27:1407-1417.
Shoup M, Gonen M, D'Angelica M, Jarnagin WR, DeMatteo RP, Schwartz LH, Tuorto S, Blumgart LH, Fong YM. Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. J Gastro Surgery 2003;7:325-330.
Singer S, Antonescu CR, Riedel E, Brennan MF. Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Annals of Surgery 2003; 238(3):358-370.
Solit DB, Basso AD, Olshen AB, Scher H, Rosen N. Inhibition of heat-shock-protein-90 function down-regulates Akt kinase and sensitizes tumors to taxol. Cancer Res 2003;63:2139-2144.
Solit DB, Morris M, Slovin S, Curley T, Schwartz L, Larson S, Kattan MW, Hartley-Asp B, Scher HI, Kelly WK. Clinical experience with intravenous estramustine phosphate, paclitaxel and carboplatin in patients with castrate metastatic prostate adenocarcinoma. Cancer 2003; 98(9): 1842-1848.
Sowers R, Toguchida J, Qin J, Meyers PA, Healey JH, Huvos A, Banerjee D, Bertino JR, Gorlick R. Messenger-RNA expression levels of E2F transcription factors correlate with dihydrofolate-reductase, reduced folate carrier, and thymidylate synthase messenger-RNA expression in osteosarcoma. Mol Canc Th 2003;2:535-541.
Staack A, Kassis AP, Olshen AB, Wang Y, Wu D, Carroll PR, Grossfeld GD, Cunha GR, Hayward SW. Quantitation of apoptotic activity following castration in human prostatic tissue in vivo. The Prostate 2003;54:212-219.
Stellman SD, Chen Y, Muscat JE, Djordjevic MV, Richie JP, Lazarus P, Thompson S, Altorki N, Berwick M, Citron ML, Harlap S, Kaur T, Neugut AI, Olson S, Travaline JM, Witorsch P, Zhang Z-F. Lung cancer risk in white and black Americans. Annals of Epidemiology 2003;13:294-302.
Swindle PW, Kattan MW, Scardino PT. Markers and meaning of primary treatment failure of carcinoma of the prostate. Urol Clin N Am 2003;30:377-401.
Teruya-Feldstein J, Donnelly GB, Goy A, Hegde A, Nanjangud G, Qin J, Thaler H, Gilles F, Dyomin VG, Lloyd KO, Zelenetz AD, Houldsworth J, Chaganti RS. MUC-1 mucin protein expression in b-cell lymphomas. Appl Immuno 2003;11:28-32.
Trabulsi EJ, Scardino PT, Kattan MW: The Decision-making Process for Prostate Cancer. In: Mydlo JH and Godec CJ (eds). The Handbook of Prostate Cancer. Academic Press: Amsterdam, San Diego; 2003: 232-252.
Ulaner GA, Huang H-Y, Otero J, Ben-Porat L, Satagopan JM, Zhao Z, Gorlick R, Meyers P, Healey JH, Huvos AG, Hoffman AR, Ladanyi M. Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma. Cancer Research 2003;63:1759-63.
Ulaner GA, Huang H-Y, Otero J, Zhao Z, Ben-Porat L, Satagopan JM, Gorlick R, Meyers P, Healey JH, Huvos AG, Hoffman AR, Ladanyi M. Absence of telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma. Cancer Research 2003;63:1759-1763.
Van Zee KJ, Manasseh DE, Bevilacqua JLB, Boolbol SK, Fey JV, Tan LK, Borgen PI, Cody III HS, Kattan MW. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Annals of Surgical Oncology 2003; 10(10): 1140-1151.
Veltman JA, Fridlyand J, Pejavar S, Olshen AB, Korkola JE, DeVries S, Carroll P, Kuo W-L, Pinkel D, Albertson D, Cordon-Cardo C, Jain AN, Waldman FM. Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors. Cancer Research 2003;63:2872-2880.
Verbel DA, Kelly WK, Smaletz O, Regan K, Curley T, Heller G, Scher HI. Estimating survival benefit in castrate metastatic prostate cancer - decision making in proczeeding to a definitive phase III trial. Urology 2003; 61:142-144.
Vickers AJ, McCarney R. Use of a single global assessment to reduce missing data in a clinical trial with follow-up at one year. Controlled Clinical Trials 2003;24(6):731-5
Vickers AJ, Zollman CE. Complementary therapies. In: Jones R, Britten N, Culpepper L, Gass D, Grol R, Mant D, Silagy C, editors. Oxford Textbook of Primary Medical Care. Oxford: Oxford University Press, 2003
Vickers AJ. Complementary cancer therapies (book review). Complementary Therapies in Medicine 2003;11:125
Vickers AJ. How many repeated measures in repeated measures designs? Statistical issues for comparative trials. BMC Medical Research Methodology 2003;3:22
Vickers AJ. Underpowering in randomized trials reporting a sample size calculation. Journal of Clinical Epidemiology 2003;56(8):717-20
Vitkup D, Sander C, Church GM. The amino-acid mutational spectrum of human genetic disease. Genome Biology 2003;4:R72.
Wang ES, Straus DJ, Teruya-Feldstein J, Qin J, Portlock C, Moskowitz C, Goy A, Hedrick E, Zelenetz AD, Noy A. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. Cancer 2003;98:1196-1205.
Westermark U, Reyngold M, Olshen AB, Baer R, Jasin M, Moynahan M. BARD1 participates with BRCA1 in homology-directed repair of chromosome breaks. Molecular and Cellular Biology 22003;23:7926-7936.
Yamada Y, Potters L, Zaider M, Cohen G, Venkatraman E, Zelefsky MJ. Impact of intraoperative edema during transperineal permanent prostate brachytherapy on computer-optimized and preimplant planning techniques. Am J Clin Oncol 2003;26:130-135.
Yeung HWD, Grewal RK, Gonen M, Schoder H, Larson SM. Patterns of 18F-FDG Uptake in Adipose Tissue and Muscle: A Potential Source of False-Positives for PET. J Nucl Med 2003;44:1789-1796
Yossepowitch O, Olvera N, Ben Porat L, Satagopan JM, Huang H, Jhanwar S, Rapaport B, Boyd J, Offit K. BRCA1 and BRCA2 germline mutations in lymphoma patients. Leukemia and Lymphoma 2002;44:127-131.
Yossepowitch O, Trabulsi EJ, Kattan MW, Scardino, PT: Predictive factors in prostate cancer: implications for decision making. Cancer Invest 2003;21:465-80.
Zakian KL, Eberhardt S, Hricak H, Shukla-Dave A, Kleinman S, Muruganandham M, Sircar K, Kattan MW, Reuter V, Scardino P, Koutcher JA. Transition zone prostate cancer: metabolic characteristics at H MR spectroscopic imaging - initial results. Radiology 2003; 229(1):241-247.
Zakian KL, Shukla-Dave A, Meyers P, Gorlick R, Healey J, Thaler HT, Huvos AG, Panicek DM, Koutcher JA. Identification of prognostic markers in bone sarcomas using proton-decoupled phosphorus magnetic resonance spectroscopy. Cancer Res 2003;63:9042-9047.
Zeana C, Larson E, Sahni J, Bayuga SJ, Wu F, Della-Latta P. The epidemiology of multidrug-resistant Acinetobacter baumannii: does the community represent a reservoir? Infect Control Hosp Epidemiol. 2003 Apr;24(4):275-9.
Zelefsky MJ, Fuks Z, Hunt M, Yamada Y, Marion C, Ling CC, Amols H, Venkatraman ES, Leibel SA, Ritter MA. High dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Urol Oncol 2003;21:306-307.
Zelefsky MJ, Yamada Y, Marion C, Sim S, Cohen G, Ben-Porat L, Silvern D, Zaider M. Improved conformality and decreased toxicity with intraoperative computer-optimized transperineal ultrasound-guided prostate brachytherapy. In J Rad O 2003;55:956-963.
